Search Our Scientific Publications & Authors

Curr Hematol Malig Rep 2021 Feb 25. Epub 2021 Feb 25.

Department of Stem Cell Transplant and Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Purpose Of Review: Chimeric antigen receptor T-cell (CAR-T) therapy is a form of adoptive cellular therapy that has revolutionized the treatment landscape in hematologic malignancies, especially B-cell lymphomas. In this review, we will discuss some of the landmark data behind these therapies and then lay out our approach to utilizing this new therapy.

Recent Findings: CD19-directed CAR-Ts are the most common type currently used in treatment of relapsed B-cell lymphoid neoplasms. Read More

Wien Med Wochenschr 2021 Feb 22. Epub 2021 Feb 22.

"Sveti Duh" University Hospital, Department of Obstetrics and Gynecology, University of Zagreb, School of Medicine, Zagreb, Croatia.

Background: Ovarian lymphoma is a rare neoplasm and most commonly represents secondary ovarian involvement in overt systemic disease, usually of the non-Hodgkin's type.

Aim: To report a case of acute abdomen caused by torquated large ovarian lymphoma.

Case Report: We report the case of 65-year-old patient admitted to our hospital with signs and symptoms of acute abdomen. Read More

Int J Lab Hematol 2021 Feb 22. Epub 2021 Feb 22.

Molecular Cytogenetics Laboratory, Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain.

Introduction: Dysregulated NK cell-mediated immune responses contribute to tumor evasion in chronic lymphocytic leukemia (CLL), although the NK cell compartment in CLL-like monoclonal B-cell lymphocytosis (MBL) is poorly understood. In healthy individuals, human cytomegalovirus (HCMV) induces the expansion of NK cells expressing high levels of CD94/NKG2C NK cell receptor (NKR) specific for HLA-E.

Methods: We analyzed the expression of NKG2A, NKG2C, ILT2, KIR, CD161, and CD57 in 24 MBL and 37 CLL. Read More

Front Immunol 2021;12:627186. Epub 2021 Feb 4.

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

After the COVID-19 outbreak, non-evidence based guidelines were published to advise clinicians on the adjustment of oncological treatment during this pandemic. As immune checkpoint inhibitors directly affect the immune system, concerns have arisen about the safety of immunotherapy during this pandemic. However, data on the immune response in oncology patients treated with immunotherapy are still lacking. Read More

J Immunother Cancer 2021 Feb;9(2)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Background: Non-Hodgkin's lymphoma (NHL) is currently the most common malignancy among people living with HIV (PLWH) in the USA. NHL in PLWH is more frequently associated with oncogenic viruses than NHL in immunocompetent individuals and is generally associated with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less immunosuppressive than chemotherapy may decrease infection risk, improve immune control of oncogenic viruses, and ultimately allow for better lymphoma control. Read More